Evaluating the Effects of Umifenovir Compared to Lopinavir/Ritonavir in the Management of Patients with COVID-19: A Randomized Controlled Trial

• DOI: 10.54034/mic.e1566
• Publication Date: 2022-12-09T22:48:07Z
• Authors: Farzaneh Dastan; Jalal Heshmatnia; Afshin Zarghi; Payam Tabarsi; Sara Haseli; Alireza Dastan; Seyed A. Nadji; Sahar Yousefian; Saghar Barati
• Keywords: Lopinavir; Ritonavir; Lopinavir/ritonavir

Background. Due to the lack of specific safe medications for treatment COVID-19, used other similar conditions are being tested alleviate condition COVID-19 patients, resulting in acceptable outcomes some cases. Umifenovir (Arbidol®) is treat influenza viruses by inhibiting fusion virus with host cell. According previous findings, umifenovir may inhibit SARS-CoV-2 infection interfering release from inside This study aimed determine effects umifenovir, a inhibitor, versus lopinavir/ritonavir treating patients COVID-19. Methods. was randomized controlled trial consisting 90 confirmed divided into group and group. The received 100/25 mg twice, while given 200 thrice day, both groups, seven days. Outcomes included mortality rate need mechanical ventilation or intensive care unit admission. Length stay hospital ICU lab tests trend were also assessed. Results. admission significantly lower (8% vs. 27.5%; P-value = 0.02). Moreover, levels white blood cells than control day 10 (6.2 (5.3-7.4) 10.8 (9.9-13); <0.001). Conclusions. reduce compared lopinavir/ritonavir. test trends favor use.